» Articles » PMID: 22155652

The New P2Y-like Receptor G Protein-coupled Receptor 17 Mediates Acute Neuronal Injury and Late Microgliosis After Focal Cerebral Ischemia in Rats

Overview
Journal Neuroscience
Specialty Neurology
Date 2011 Dec 14
PMID 22155652
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

G protein-coupled receptor 17 (GPR17), the new P2Y-like receptor, is phylogenetically related to the P2Y and cysteinyl leukotriene receptors, and responds to both uracil nucleotides and cysteinyl leukotrienes. GPR17 has been proposed to be a damage sensor in ischemic stroke; however, its role in brain inflammation needs further detailed investigation. Here, we extended previous studies on the spatiotemporal profiles of GPR17 expression and localization, and their implications for brain injury after focal cerebral ischemia. We found that in the ischemic core, GPR17 mRNA and protein levels were upregulated at both 12-24 h and 7-14 days, but in the boundary zone the levels increased 7-14 days after reperfusion. The spatiotemporal pattern of GPR17 expression well matched the acute and late (subacute/chronic) responses in the ischemic brain. According to previous findings, in the acute phase, after ischemia (24 h), upregulated GPR17 was localized in injured neurons in the ischemic core and in a few microglia in the ischemic core and boundary zone. In the late phase (14 days), it was localized in microglia, especially in activated (ED1-positive) microglia in the ischemic core, but weakly in most microglia in the boundary zone. No GPR17 was detectable in astrocytes. GPR17 knockdown by a small interfering RNA attenuated the neurological dysfunction, infarction, and neuron loss at 24 h, and brain atrophy, neuron loss, and microglial activation at 14 days after reperfusion. Thus, GPR17 might mediate acute neuronal injury and late microgliosis after focal cerebral ischemia.

Citing Articles

Characterisation of GPR17-expressing oligodendrocyte precursors in human ischaemic lesions and correlation with reactive glial responses.

Raffaele S, Clausen B, Mannella F, Wirenfeldt M, Marangon D, Tidgen S J Pathol. 2024; 265(2):226-243.

PMID: 39703181 PMC: 11717493. DOI: 10.1002/path.6381.


GPR17 modulates anxiety-like behaviors basolateral amygdala to ventral hippocampal CA1 glutamatergic projection.

Nie R, Zhou X, Fu J, Hu S, Zhang Q, Jiang W Acta Pharm Sin B. 2024; 14(11):4789-4805.

PMID: 39664418 PMC: 11628806. DOI: 10.1016/j.apsb.2024.08.005.


Static Magnetic Stimulation and Magnetic Microwires Synergistically Enhance and Guide Neurite Outgrowth.

Neuman K, Zhang X, Lejeune B, Pizzarella D, Vazquez M, Lewis L Adv Healthc Mater. 2024; 14(3):e2403956.

PMID: 39568232 PMC: 11773108. DOI: 10.1002/adhm.202403956.


Insulin-Like Growth Factor 1 Has the Potential to Be Used as a Diagnostic Tool and Treatment Target for Autism Spectrum Disorders.

Shen J, Liu L, Yang Y, Zhou M, Xu S, Zhang W Cureus. 2024; 16(7):e65393.

PMID: 39188438 PMC: 11346671. DOI: 10.7759/cureus.65393.


Knockdown and inhibition of hippocampal GPR17 attenuates lipopolysaccharide-induced cognitive impairment in mice.

Liang Y, Kang X, Zhang H, Xu H, Wu X J Neuroinflammation. 2023; 20(1):271.

PMID: 37990234 PMC: 10662506. DOI: 10.1186/s12974-023-02958-9.